comparemela.com
Home
Live Updates
Iptacopan Reduces Proteinuria, Demonstrates Benefit in C3 Glomerulopathy : comparemela.com
Iptacopan Reduces Proteinuria, Demonstrates Benefit in C3 Glomerulopathy
In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.
Related Keywords
Sweden
,
Stockholm
,
,
G Steering Committee Member David Kavanagh
,
Novartis
,
European Renal Association Congress
,
Foundation Trust David Kavanagh
,
Faculty Of Medical Sciences At Newcastle University
,
David Kavanagh
,
Steering Committee Member David Kavanagh
,
Complement Therapeutics
,
Honorary Consultant Nephrologist
,
Medical Sciences
,
European Renal Association
,
comparemela.com © 2020. All Rights Reserved.